Evotec have initiated a Phase I clinical study of its proprietary, small molecule P2X7 receptor antagonist … more →
GPCR Newscrimsoncanary wrote 1 month ago: Evotec have initiated a Phase I clinical study of its proprietary, small molecule P2X7 receptor ant … more →
crimsoncanary wrote 3 months ago: Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanill … more →
crimsoncanary wrote 3 months ago: Evotec AG have announced the initiation of a Phase I clinical trial of a small molecule VR1 (vanill … more →
silico wrote 1 year ago: In September 2006 the German pharmaceutical company, Merck KGaA, acquired Europe’s largest bio … more →